期刊文献+

MMP-3在乳腺导管癌中的表达及临床意义 被引量:3

Expression and clinical significance of MMP-3 in breast ductal carcinomas
下载PDF
导出
摘要 目的:检测MMP-3在乳腺导管癌中的表达,探讨其临床意义及与乳腺导管癌临床病理参数的关系。方法:应用免疫组化MaxVision法检测48例乳腺导管癌患者MMP-3的表达,分析MMP-3与乳腺导管癌患者的年龄、肿瘤大小、组织学类型、淋巴结转移及肿瘤ER、PR、E-cad、C-erbB-2的关系。结果:MMP-3在乳腺导管癌组织中的阳性表达显著高于乳腺正常组织(P<0.05)。MMP-3在无淋巴结转移和C-erb-B阳性的乳腺导管癌组织的阳性表达率显著高于相应对照组(P<0.05);而在不同年龄、肿瘤大小、组织学类型及肿瘤ER、PR、E-cad、C-erbB-2分组间的表达无显著差异(P>0.05)。结论:MMP-3在无淋巴结转移的乳腺导管癌组织高表达,和较早阶段乳腺导管癌的发生发展密切相关,将有可能预测高危人群作出早期诊断;MMP-3在C-erbB-2阳性的乳腺导管癌组织显著高表达,联合检测这两个指标对判断乳腺导管癌的预后可能有重要意义。 Objective:To detect the expression of MMP -3 in breast ductal carcinomas, and explore its significance and the relationship with clinical parameters. Methods : The expression of MMP - 3 was detected in 48 cases of breast ductal carcinomas by immunohistochemistry MaxVision, and to analyze the relation between MMP- 3 and breast ductal carcinomas patient age, tumor size,histological type,lymph node metastasis, ER, PR, E - cad and C - erbB -2. Results: MMP -3 in breast ductal carcinomas positive rate was significantly higher than normal breast tissue(P 〈0.05 ). M MP- 3 rate in patients without lymph node metastasis and positive C -erbB -2 was significantly higher than those in the control group ( P 〈 0.05 ) ; but in different age, tumor size, histological type and ER, PR, E - cad and C - erbB - 2 no significant difference ( P 〉 0.05 ). Conclusion : MMP - 3 is highly expressed in patients without lymph node metastasis and early stages of breast ductal carcinomas MMP - 3 in C - erbB - 2 positive breast ductal carcinomas is significantly higher expressed, combined detecton of these two indexes in predicting the prognosis of ductal breast cancer could have important implications.
出处 《现代肿瘤医学》 CAS 2011年第2期274-276,共3页 Journal of Modern Oncology
基金 洛阳市应用技术研究与开发基金项目(编号:0802021A)
关键词 乳腺导管癌 基质金属蛋白酶-3 免疫组织化学 breast ductal carcinomas MMP - 3 immunohistochemistry
  • 相关文献

参考文献9

  • 1Chambers AF, Matrislan LM. Changing view of the role of matrix metaUoproteinases in metastasis [ J ]. J Natl Cancer Inst, 1997,89 (7) :1260 - 1270.
  • 2于秀文,程慧,王静芬.大肠癌组织中MMP-3的表达及其临床意义[J].中华肿瘤防治杂志,2006,13(1):45-47. 被引量:11
  • 3Frina AR, Taeonelli A, Cappabianca L, et aL Inhibition of human MDA - MB -231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plaminogen[ J ]. Eur J Biochem, 2002,269 ( 18 ) :4476 - 4483.
  • 4Mesherry EA, Donatello S, Hopkin AM, et al. Molecular basis of invasion in breast cance[ J ]. Cell Mol Lif Sci, 2007,164 ( 24 ) : 3201-3218.
  • 5Sternlicht MD, Bissell M J, Werb Z. The matrix metalloproteinase stromelysin - 1 act as a natural mammary tumor [ J]. Oncogene, 2000,19(8) :1102 - 1113.
  • 6Balduyck M,Zerimech F, Gouyer V, et al. Sepcific expression of matrix metalloproteinasesl, 3,9 andl3 associate with invasion of breast cancer in vitro [ J]. Clin Exp Metsstasis,2000,18 (2) : 171 -178.
  • 7向志刚 杨竹林.细胞外基质蛋白酶诱导因子与恶性肿瘤.国外医学:临床生物化学与检验学分册,2001,9:1210-1213.
  • 8Brummer O, Athar S, Riethdorf L, et al. Matrix metalloproteinase 1, 2,3 and their tissue inhibitors 1,2 in benign and malignant breast lesions : an in situ hybridization study [ J ]. Virchows Arch, 1999, d35(3) :566-573.
  • 9Yamauchi H, Steams V, Hayes DF. When is a tumor mark ready for prime time? A case study of C - erbB - 2 as a predictive factor in breast cancer[ J]. Clin Oncol,2001,19:2354 -2386.

二级参考文献6

  • 1Kleiner D E,Stetler-Stevenson W G.Matrix metalloproteinases and metastasis[J].Cancer Chemother Pharmacol,1999,43 (Suppl):42-51.
  • 2Jass J R,Sobin L H.Histological typing of intestinal tumors.World Health Organization international histological classification of Tumors[M].2nd ed.New York:Springer-Verlag,1989.
  • 3Muller D,Wolf C,Abecassis J,et al.Increased stromelysin 3gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas[J].Cancer Res,1993,53(1):165-169.
  • 4Bodey B,Bodey B Jr,Siegel S E,et al.Prognostic significance of matrix metalloproteinases expression in colorectal carcinomas[J].In Vivo,2000,14(5):659-666.
  • 5陈美芳,季峰,厉有名.食管癌基质金属蛋白酶及其组织抑制剂表达的研究[J].中华消化杂志,2002,22(3):181-183. 被引量:15
  • 6韩金利.基质金属蛋白酶和膀胱癌研究进展[J].广州医药,2002,33(3):4-7. 被引量:5

共引文献10

同被引文献54

  • 1于学燕,王永刚.MMP-2和MMP-3在非小细胞肺癌组织中的表达及意义[J].现代肿瘤医学,2005,13(4):461-463. 被引量:5
  • 2于秀文,程慧,王静芬.大肠癌组织中MMP-3的表达及其临床意义[J].中华肿瘤防治杂志,2006,13(1):45-47. 被引量:11
  • 3Sφrlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinicalimplications[J].Proc Natl Acad Sci USA,2001,98(19):10869-10874.
  • 4Aksoy S,Dizdar O,Harputluoglu H,et al.Demographic,clinical,and pathological characteristics of Turkish triple-negative breast cancer patients:single center experience[J].Ann Oncol,2007,18(11):1904-1906.
  • 5Baker EA,Stephenson TJ,Reed MW,et al.Expression of proteinases and inhibitors in human breast cancer progression and survival[J].Mol Pathol,2002,55(5):300-304.
  • 6Sauter ER,Nesbit M,Watson JC,et al.Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck[J].Clin Cancer Res,1999,5(4):775-782.
  • 7Adams J,Carder PJ,Downey S,et al.Vascular endothelial growth factor (VEGF) in breast cancer:comparison of plasma,serum,and tissue VEGF and microvessel density and effects of tamoxifen[J].Cancer Res,2000,60(11):2898-2905.
  • 8Shimizu M,Saitoh Y,Itoh H.Immunohistochemical staining of Ha-ras oncogene product in normal,benign,and malignant human pancreatic tissues[J].Cancer Res,1990,21(6):607-612.
  • 9Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(16):5367-5374.
  • 10Li J,Zhang YP,Kirsner RS.Angiogenesis in wound repair:angiogenic growth factors and the extracellular matrix[J].Microsc Res Tech,2003,60(1):107-114.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部